Here are 5 important questions to ask if you’ve been told you have cervical dysplasia: ...

Opens in a new tab or window Testing for somatic genomic copy number alterations (CNAs) in ulcerative colitis patients with low-grade dysplasia was able to predict risk of advanced neoplasia more ...

“Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16-associated CIN3 lesions and clearing the underlying persistent HPV16 ...

Background The risk of developing advanced neoplasia (AN; colorectal cancer and/or high-grade dysplasia) in ulcerative colitis (UC) patients with a low-grade dysplasia (LGD) lesion is variable and ...

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

Future risk prediction models could incorporate measures of obesity to improve stratification among patients with Barrett’s ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published ...

Some oncologists suggest that, for certain early cancers not at risk of spreading, the term “cancer” should be avoided.

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.

Cervical cancer screening traditionally relies on the Pap smear and HPV-DNA tests. While effective, these methods are fraught with challenges, including variability in human interpretation, false ...